EcoDrugPlus

Phosphodiesterase 4d

Ensembl ID : ENSDCDG00000000665
Gene Symbol: PDE4D
3 Cross references
144 Possible Orthologues:

Phosphodiesterase 5a

Ensembl ID : ENSDCDG00000012512
Gene Symbol: PDE5A
3 Cross references
209 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSDCDG00000023603
Gene Symbol: PDE7A
3 Cross references
167 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSDCDG00000025086
Gene Symbol: PDE7A
3 Cross references
215 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSDCDG00000010793
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 1

Ensembl ID : ENSDCDG00000019199
Gene Symbol: PIK3R1
3 Cross references
253 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSDCDG00000033675
Gene Symbol: PIK3R2
3 Cross references
190 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSDCDG00000033897
Gene Symbol: PIK3R2
3 Cross references
190 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSDCDG00000029931
Gene Symbol: PIK3R3
3 Cross references
188 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSDCDG00000002371
Gene Symbol: PIK3R5
3 Cross references
202 Possible Orthologues:

Phospholipase A2 Group Vii

Ensembl ID : ENSDCDG00000035533
Gene Symbol: PLA2G7
3 Cross references
206 Possible Orthologues:

Phospholipase A2 Group X

Ensembl ID : ENSDCDG00000020220
Gene Symbol: PLA2G10
1 Cross references
231 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).